Eli Lilly (LLY) has a Weight Loss Drug Pipeline to Drive Growth for Years to Come
April 7, 2026
Eli Lilly (LLY) has two blockbusters with Mounjaro and Zepbound. It also has new drugs coming to drive growth for years to come.
Research Reports
Mounjaro and Zepbound Drive Eli Lilly (LLY) Stock to an All-Time High
January 8, 2026
Eli Lilly (LLY) stock reaches an All-Time High in late November, fueled by strong performances from Mounjaro and Zepbound.
Eli Lilly’s (LLY) Mounjaro and Zepbound Could Become Available in a Pill in 2026
September 26, 2025
Eli Lilly’s (LLY) Mounjaro sales jumped 68% last qtr while Zepbound sales surged 172% as these two now make up half LLY’s sales.
Eli Lilly (LLY) Shows Zepbound Helps Patients Lose More Weight than Wegovy
June 2, 2025
Eli Lilly (LLY) stated its weight loss drug helped nearly 25% more participants lose more than 15% of their weight vs. Nova Nordisk’s.
Eli Lilly’s (LLY) Weight Loss Drugs Mounjaro and Zepbound Continue to Drive Profits
March 27, 2025
Eli Lilly’s (LLY) Mounjaro and Zepbound continue to drive company revenue and profits higher as the pair now accont for 40% of sales.
Eli Lilly (LLY) Drops After Company Misses Estimates, But the Future is Still Bright
December 19, 2024
Eli Lilly (LLY) stock has weakened lately, but the company is set toprofit handomely in the upcoming years from Mounjaro & Zepbound.
Eli Lilly (LLY) is Increasing Output of its Diabetes, Weightless, and Alzheimer’s Drugs
October 10, 2024
Eli Lilly (LLY) has ramped up production of its Mounjaro diabetes drug, Zepbound weight loss drug, and Kisunla its Alzheimer’s drug.
Eli Lilly (LLY) Stock Climbs as Mounjaro and Zepbound Push Revenue Higher
June 18, 2024
Eli Lilly (LLY) has two blockbuster drugs Mounjaro and Zepbound boosting sales. Meanwhile, the company couldn’t make enough .
Demand Increases for Eli Lilly’s (LLY) Mounjaro With Delays in Filling Orders
April 21, 2024
Eli Lilly (LLY) can’t keep up with demand for Mounjaro, and now it has to make Zepbound too. That’s good news for shareholders.
Eli Lilly’s (LLY) Profit Potential with Drugs Mounjaro and Zepbound is Exceptional
January 7, 2024
Eli Lilly (LLY) could be a leading stock for 2024 as its diabetes drug Mounjaro and its weight loss drug Zepbound are now available.
Eli Lilly (LLY) Stock Climbs After Mounjaro Sales Soar; Wegovy’s Heart Study
August 29, 2023
Eli Lilly (LLY) stock jumped following earnings which saw its diabetes drug Monjaro sales soar and news it could reduce heart risk.
Eli Lilly (LLY) Stock Soar on the Back of Two Potential Blockbuster Drugs
June 12, 2023
Eli Lilly (LLY) shares have been soaring as Mounjaro for weight loss and Donanemab for Alzeimer’s could fuel profits for years.
Drug Maker Eli Lilly (LLY) Caps the Price of Insulin to $35 a Month
March 7, 2023
Eli Lilly (LLY) capped the price of insulin it provides to Americans at $35 a month. But LLY’s weight loss drug should be the big news.
Eli Lilly (LLY) Might Have a Weight Loss Drug that Could Be a Blockbuster
December 1, 2022
Eli Lilly (LLY) continues to rise as it has developed what could become the next big weight loss drug, pending approval from the FDA.
Eli Lilly (LLY) Has Two New Drugs That Could Become Blockbusters
September 28, 2022
Eli Lilly (LLY) has two potential blockbuster drugs — for weight loss and Alzheimer’s — that could bring big profits down the road.